WEBSTER, Texas, October 21, 2010 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line. The initial uses of the newly introduced 180mm and 200mm stents occurred in August of this year, followed by a full European market launch at the recent European Society of Vascular Surgery meeting held this past September, in Amsterdam.

SUPERA stents are well known for their radial strength and flexibility that results from the unique wire interwoven nitinol design, which also provides high resistance to kinking/fracturing. The new 180mm and 200mm sizes are designed for the treatment of long lesions in patients with peripheral vascular disease.

We are very pleased with the acceptance of these new longer stents. Our goal is to provide the broadest and most effective line of products for treating patients with peripheral vascular disease. The successful launch of these additional SUPERA sizes moves us closer to reaching that goal and achieves our objective of launching multiple new products in Europe this year, stated Christopher M. Owens, President and CEO of IDEV.

The launch of these devices follows the recent introduction of the SUPERA VERITAS(TM) Peripheral Vascular System, an easy to use, reliable and more precise delivery system developed to deliver the SUPERA stent.

Peter Haarbrink, MD, a leading interventional radiologist affiliated with Canisius Wilhelmina Ziekenhuis (CWZ), a large general and teaching hospital located in Nijmegen, The Netherlands, said, The availability of these new sizes has given me even more options for treating patients with peripheral vascular disease. The unique and exceptional stent properties, combined with the ease of delivery with the new VERITAS(TM) system, create a true advancement in technology.

Dierk Scheinert, MD, and Chairman of the Center for Vascular Medicine at the Park Hospital, Leipzig, Germany, was one of the first to deploy the longer sizes. He concluded, I've used the SUPERA product for several years and appreciate the ongoing enhancements to the system. First VERITAS made it easier and more accurate to deploy the stent. Now the 180mm and 200mm sizes allow me to treat longer and more difficult lesions, they deploy easily and add to a broad stent portfolio.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology marketplace. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands. Please visit http://www.idevmd.com.

The SUPERA stent is currently indicated in the US for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe for both the treatments of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

Contact: William W. Burke Executive Vice President Chief Financial Officer IDEV Technologies, Incorporated +1-281-525-2000 Donna Lucchesi Vice President Global Marketing IDEV Technologies, Incorporated +1-281-525-2000

SOURCE: IDEV Technologies, Incorporated

CONTACT: William W. Burke, Executive Vice President Chief FinancialOfficer, or Donna Lucchesi, Vice President Global Marketing, both of IDEVTechnologies, Incorporated, +1-281-525-2000